Phase II study of anti-CD3 x anti-HER2/neu (HERBi) armed activated T cells (ATC) after neoadjuvant chemotherapy in patients with HER2/neu (0-2+)-negative stage II-III breast cancer

被引：0
|
作者：
Bumma, Naresh [1 ]
Kin, Andrew [1 ]
Abrams, Judith [1 ]
Deol, Abhinav [1 ]
Weise, Amy [1 ]
Thakur, Archana [2 ]
Lum, Lawrence [2 ]
机构：
[1] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[2] Univ Virginia, Ctr Canc, Charlottesville, VA 22908 USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P207
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II clinical trial using anti-CD3 x anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer
    Lum, Lawrence G.
    Al-Kadhimi, Zaid
    Deol, Abhinav
    Kondadasula, Vidya
    Schalk, Dana
    Tomashewski, Elyse
    Steele, Patricia
    Fields, Kristie
    Giroux, Melissa
    Liu, Qin
    Flaherty, Lawrence
    Simon, Michael
    Thakur, Archana
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (06)
  • [2] Phase II clinical trial using anti-CD3 x anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) for HER2-negative (0-2+) metastatic breast cancer.
    Lum, Lawrence G.
    Thakur, Archana
    Al-Kadhimi, Zaid S.
    Deol, Abhinav
    Simon, Michael S.
    Schalk, Dana
    Liu, Qin
    Flaherty, Lawrence E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Fate and function of anti-CD3 activated T cells (ATC) armed with OKT3 x anti-Her2/Neu bispecific antibody (Her2Bi) in patients with Her2/neu+ tumors
    Lum, L
    Grabert, R
    Gall, J
    Kouttab, N
    JOURNAL OF IMMUNOTHERAPY, 2003, 26 (06): : S21 - S21
  • [4] Activated T Cells (ATC) Armed with Anti-CD3 X Anti-Her2/Neu Bispecific Antibody (Her2Bi) Is a Potent Immunomodulator.
    Norkina, Oxana
    Thakur, Archana
    Norkin, Maxim
    Paul, Elyse
    Al-Kadhimi, Zaid
    Lum, Lawrence G.
    BLOOD, 2008, 112 (11) : 888 - 888
  • [5] Activated T cells armed with anti-CD3 x anti-HER2/neu bispecific antibody III.: Kinetics and survival of armed ATC in prostate cancer patients.
    Rathore, R
    Colvin, GA
    Kouttab, NM
    Falvey, MT
    Grabert, RC
    Smith, JA
    Tiggs, JC
    Cohen, IC
    Maizel, AL
    Quesenberry, PJ
    Elfenbein, GJ
    Lum, LG
    BLOOD, 2002, 100 (11) : 54B - 54B
  • [6] Activated T cells armed with anti-CD3 x anti-HER2/neu bispecific antibody II.: Armed ATC target, kill, divide, and survive.
    Grabert, RC
    Smith, JA
    Kouttab, NM
    Tiggs, JC
    Lum, LG
    BLOOD, 2002, 100 (11) : 55B - 55B
  • [7] Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors
    Sen, M
    Wankowski, DM
    Garlie, NK
    Siebenlist, RE
    Van Epps, D
    LeFever, AV
    Lum, LG
    JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2001, 10 (02): : 247 - 260
  • [8] Phase I immunotherapy in women with metastatic breast cancer with activated T cells targeted with anti-CD3 x anti-Her2/neu bispecific antibody
    Lum, L. G.
    Al-Kadhimi, Z.
    Skuba, C.
    Sandborg, R.
    Rathore, R.
    Liu, Q.
    Uberti, J. P.
    Ratanatharathorn, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Induction of immune responses and improved survival after infusions of T cells armed with anti-CD3 x anti-Her2/Neu bispecific antibody in stage IV breast cancer patients (Phase I)
    Lum, Lawrence G.
    Rathore, Ritesh
    Dizon, Don
    Wang, Ding
    Al-Kadhimi, Zaid
    Uberti, Joseph P.
    Ratanatharathorn, Voravit
    BLOOD, 2007, 110 (11) : 807A - 807A
  • [10] Activated T cells armed with anti-CD3 x anti-HER2/neu bispecific antibody I:: Anti-tumor activity and survival in SCID/Beige mice.
    Smith, JA
    Davol, PA
    Kouttab, NM
    Rathore, R
    Elfenbein, GJ
    Lum, LG
    BLOOD, 2002, 100 (11) : 673A - 673A
12345